Chilà R - Search Results

1

Role and therapeutic potential of CDK12 in human cancers.

Chilà R, Guffanti F, Damia G. Chilà R, et al. Cancer Treat Rev. 2016 Nov;50:83-88. doi: 10.1016/j.ctrv.2016.09.003. Epub 2016 Sep 14. Cancer Treat Rev. 2016. PMID: 27662623 Review.

2

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

Carrassa L, Chilà R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M, Damia G. Carrassa L, et al. Among authors: chila r. Cell Cycle. 2012 Jul 1;11(13):2507-17. doi: 10.4161/cc.20899. Epub 2012 Jul 1. Cell Cycle. 2012. PMID: 22713237

3

Chk1-Mad2 interaction: a crosslink between the DNA damage checkpoint and the mitotic spindle checkpoint.

Chilà R, Celenza C, Lupi M, Damia G, Carrassa L. Chilà R, et al. Cell Cycle. 2013 Apr 1;12(7):1083-90. doi: 10.4161/cc.24090. Epub 2013 Mar 1. Cell Cycle. 2013. PMID: 23454898 Free PMC article.

4

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.

Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L. Chilà R, et al. Oncotarget. 2015 Feb 20;6(5):3394-408. doi: 10.18632/oncotarget.2583. Oncotarget. 2015. PMID: 25428911 Free PMC article.

5

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G, Carrassa L. Restelli V, et al. Among authors: chila r. Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954. Oncotarget. 2015. PMID: 26439697 Free PMC article.

6

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.

de Oliveira SF, Ganzinelli M, Chilà R, Serino L, Maciel ME, Urban Cde A, de Lima RS, Cavalli IJ, Generali D, Broggini M, Damia G, Ribeiro EM. de Oliveira SF, et al. Among authors: chila r. PLoS One. 2016 Jan 11;11(1):e0145647. doi: 10.1371/journal.pone.0145647. eCollection 2016. PLoS One. 2016. PMID: 26751376 Free PMC article.

7

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.

Guffanti F, Chilà R, Bello E, Zucchetti M, Zangarini M, Ceriani L, Ferrari M, Lupi M, Jacquet-Bescond A, Burbridge MF, Pierrat MJ, Damia G. Guffanti F, et al. Among authors: chila r. Neoplasia. 2017 Jan;19(1):35-42. doi: 10.1016/j.neo.2016.11.008. Epub 2016 Dec 15. Neoplasia. 2017. PMID: 27988457 Free PMC article.

8

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.

Chilà R, Hall G T, Abbadessa G, Broggini M, Damia G. Chilà R, et al. Transl Oncol. 2017 Apr;10(2):153-157. doi: 10.1016/j.tranon.2016.12.003. Epub 2017 Feb 3. Transl Oncol. 2017. PMID: 28161661 Free PMC article.

9

Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.

Restelli V, Lupi M, Vagni M, Chilà R, Bertoni F, Damia G, Carrassa L. Restelli V, et al. Among authors: chila r. Target Oncol. 2018 Apr;13(2):235-245. doi: 10.1007/s11523-018-0553-6. Target Oncol. 2018. PMID: 29441438

10

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chilà R, Sina FP, Fruscio R, Lupia M, Cavallaro U, Cappelletti MR, Generali D, Giavazzi R, Damia G. Guffanti F, et al. Among authors: chila r. Oncotarget. 2018 May 15;9(37):24707-24717. doi: 10.18632/oncotarget.25185. eCollection 2018 May 15. Oncotarget. 2018. PMID: 29872499 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21 results

Search Page